Anticonvulsants for cocaine dependence

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 4, 2015, Pages

  Minozzi, Silvia ^a   Cinquini, Michela ^b   Amato, Laura ^a   Davoli, Marina ^a   Farrell, Michael F ^c   Pani, Pier Paolo ^d   Vecchi, Simona ^a  

^a DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Social Health Division   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; COCAINE; DESIPRAMINE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; PLACEBO; TIAGABINE; TOPIRAMATE; VIGABATRIN;

ADDICTION SEVERITY INDEX; CLINICAL GLOBAL IMPRESSION SCALE; COCAINE DEPENDENCE; CONFIDENCE INTERVAL; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HEART DEATH; HUMAN; PATIENT DROPOUT; PRIORITY JOURNAL; REVIEW; RISK; SELF REPORT; SYSTEMATIC REVIEW; COCAINE-RELATED DISORDERS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICONVULSANTS; COCAINE-RELATED DISORDERS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84944451215     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006754.pub4     Document Type: Review

References (128)

1. Berger PS, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005;100(Suppl 1):58-67.
2. Berger PS, Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Leiderman DB, et al. A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. Addiction 2005;100(Suppl 1):58-67.
3. Bisaga A, Aharonovich E, Garawi F, Levin FR, Rubin E, Raby WN, et al. A randomised placebo-controlled trial of gabapentin for cocaine dependence. Drug and Alcohol Dependence 2006;81(3):267-74.
4. Brodie JD, Case BG, Figueroa E, Dewey SL, Robinson JA, Wanderling JA, et al. Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees. American Journal of Psychiatry 2009;166(11):1269-77.
5. Brown ES. Comparative medication strategies in treatment trials for bipolar disorder and substance use disorders. Bipolar Disorder 2013;15:33.
6. Brown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ. A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 2012;37(11):2347-54.
7. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of Desipramine or Carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. Journal of Addictive Diseases 1994;13(4):191-9.
8. Campbell JL, Thomas HM, Gabrielli W, Liskow BI, Powell BJ. Impact of Desipramine or Carbamazepine on patient retention in outpatient cocaine treatment: preliminary findings. Journal of Addictive Diseases 1994;13(49:191-9.
9. Campbell J, Nickel EJ, Penick EC, Wallace D, Gabrrelli WF, Rowe C, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine dependent patients. American Journal of Addiction 2003;12:122-36.
10. Campbell J, Nickel EJ, Penlick EC, Liskow B, Powell BJ. Gender differences in pharmacologic treatment for cocaine dependence. NIDA Research Monograph 1999:54.
11. Campbell L, Thomas HM, Gabrielli WF, Samuelson SD. Efficacy and compliance with carbamazepine and desipramine versus placebo for cocaine abusers. NIDA Research Monograph 1996;162:147.
12. Campbell J, Nickel EJ, Penick EC, Wallace D, Gabrrelli WF, Rowe C, et al. Comparison of desipramine or carbamazepine to placebo for crack cocaine dependent patients. American Journal of Addiction 2003;12:122-36.
13. Cornish JW, Manny I, Fudala PJ, Neal S, Poole SA, Volpicelli P, et al. Carbamazepine treatment for cocaine dependence. Drug and Alcohol Dependence 1995;38(3):221-7.
14. Crosby RD, Pearson VL, Eller C, Winegarden T, Graves NL. Phenytoin in the treatment of cocaine abuse: a double blind study. Clinical Pharmacology & Therapeutics 1996;59(4):458-68.
15. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence 2007;87(1):1-9.
16. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Tiagabine increases cocaine-free urine in cocaine-dependent methadone-treated patients: results of a randomised pilot study. Addiction 2003;98(11):1625-32.
17. Gonzalez G, Desai R, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug and Alcohol Dependence 2007;87(1):1-9.
18. Halikas JA, Crosby RD, Koop LP, Crea F, Nugent SM, Carlson GA. Daily monitored cardiovascular effects of Carbamazepine in chronic crack cocaine use. Psychopharmacological Bullettin 1991;27(3):345-51.
19. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomised double-blind study of carbamazepine in the treatment of cocaine abuse. Clinical Pharmacology and Therapeutics 1997;62(1):89-105.
20. Halikas JA, Crosby RD, Koop LP, Crea F, Nugent SM, Carlson GA. Daily monitored cardiovascular effects of Carbamazepine in chronic crack cocaine use. Psychopharmacological Bullettin 1991;27(3):345-51.
21. Halikas JA, Crosby RD, Pearson VL, Graves NM. A randomised double-blind study of carbamazepine in the treatment of cocaine abuse. Clinical Pharmacology and Therapeutics 1997;62(1):89-105.
22. Johnson BA, Ait-Daoud N, Wang XQ, Penberthy K, Javors MA, Seneviratne C, Liu L. Topiramate for the treatment of cocaine addiction: a randomised clinical trial. JAMA Psychiatry 2013;70(12):1388-46.
23. Kampan KM, Pettinati H, Lynch KG, Dackis C, Sparkman T, Weigley C, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug and Alcohol Dependence 2004;75(3):233-40.
24. Kampman K, Pettinati H, Lynch K, Jones A, Varillo K, O'Brian C. A double-blind, placebo controlled trial of topiramate for the treatment of comorbid alcohol and cocaine dependence. Neuropsychopharmacology. 2010; Vol. 35(Suppl 1):S207.
25. Kampman KM, Pettinati HM, Lynch KG, et al. Topiramate for the treatment of comorbid alcohol and cocaine dependence. Proceedings of the 73rd Annual Scientific Meeting of the College on Problems of Drug Dependence;. Hollywood, Florida, 2011; Vol. 84:Abstract no: 334.
26. Kampman KM, Pettinatia HM, Lyncha KG, Spratt BK, Wierzbickic MR, O'Briena CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug and Alcohol Dependence 2013;133:94-9.
27. Hersh D, Bauer LO, Kranzler HR. Carbamazepine and cocaine-cue reactivity. Drug and Alcohol Dependence 1995;39:213-21.
28. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug and Alcohol Dependence 1995;38(3):203-11.
29. Montoya ID, Levin FR, Fudala PJ, Gorelick DA. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug and Alcohol Dependence 1995;38(3):213-9.
30. Nuijten M, Blanken P, van den Brink W, Hendriks V. Cocaine Addiction Treatments to improve Control and reduce Harm (CATCH): new pharmacological treatment options for crack-cocaine dependence in the Netherlands. BMC Psychiatry 2011;11:135.
31. Nuijten M, Blanken P, van den Brink W, Hendriks V. Treatment of crack-cocaine dependence with topiramate: a randomized controlled feasibility trial in The Netherlands. Drug and Alcohol Dependence 2014;138:177-84.
32. Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA, Galloway GP, et al. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 2013;70(6):630-7.
33. Umbricht A, DeFulio A, Tompkins DA. Topiramate and contingency management in the treatment of cocaine dependence: a randomized controlled trial. Proceedings of the 74th Annual Scientific Meeting of the College on Problems of Drug Dependence;. Palm Springs, CA, 2012; Vol. Abstract no: 681.
34. Umbricht A, DeFulio A, Winstanley EL, Tompkins DA, Peirce J, Mintzer MZ, et al. Topiramate for cocaine dependence during methadone maintenance treatment: a randomized controlled trial. Drug and Alcohol Dependence 2014;140:92-100.
35. Winhusen TM, Somoza EC, Harrer JM, Mezinskis JP, Montgomery MA, Goldsmith RJ, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100(Suppl 1):68-77.
36. Winhusen T, Somoza E, Ciraulo DA, Harrer JM, Goldsmith RJ, Grabowski J, et al. A double-blind, placebo-controlled trial of tiagabine for the treatment of cocaine dependence. Drug and Alcohol Dependence 2007;91(2-3):141-8.
37. Ahmadi J, Kampman K, Dackis C. Outcome predictors in cocaine dependence treatment trials. The American Journal of Addiction Psychiatry 2006;15(6):434-9.
38. Brady KT, Sonne SC, Malcolm RJ, Randall CL. Carbamazepine in the teratment of cocaine dependence: subtyping by affective disorders. Experimental and Clinical Pharmacology 2002;10(3):276-85.
39. Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla LB. Lamotrigine in patients with bipolar disorder and cocaine dependence. Journal of Clinical Psychiatry 2003;64(2):198-201.
40. Campbell J, Gorodetzky C, Nickel J, Pennick E. Does worse predict better? Characteristics and outcomes of volunteers for a medication trial or Psychosocial trial. Drud and Alcohol Dependence. Sixty-Thrid Annual Scientific Meetind Scottsdale, Arizona. 2001; Vol. Vol. 63 supplement 1, S23.
41. Cornish JW, Maany I, Fudala PJ, Poole SA, O'Brien CP. An analysis of factors influencing subject participation in a trial of carbamazepine for cocaine dependence treatment. NIDA Research Monograph 1995;135:312.
42. Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS. Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 2005;100(Suppl 1):91-101.
43. Gonzalez G, Sevarino K, Sofuoglu M, Poling J, Oliveto A, Gonsai K, et al. Tiagabine increases cocaine-free urine in cocaine-dependent methadone-treated patients: results of a randomised pilot study. Addiction 2003;98(11):1625-32.
44. Gorelick DA, Weinhold LL, Cone EJ, Henningfield JE. Carbamazepine (CBS) does not alter cocaine self-administration in human cocaine addicts. NIDA Research Monograph 1994;141:137.
45. Halikas J, Kemp K, Kuhn K, Carlson G, Crea F. Carbamazepine for cocaine addiction. The Lancet 1989;1(8638):623-4.
46. Halikas JA, Crosby RD, Carlson GA, Crea F, Graves NM, et al. Cocaine reduction in unmotivated crack users using carbamazepine versus placebo in a short term, double blind cross over design. Clinical Pharmacology & Therapeutics 1991;50:81-95.
47. Haney M, Hart C, Collins ED, Foltin RW. Smoked cocaine discrimination in humans: effects of gabapentin. Drug and Alcohol Dependence 2005;80(1):53-61.
48. Hart CL, Waerd AS, Collins ED, Haney M, Foltin RW. Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug and Alcohol Dependence 2004;73(3):279-87.
49. Hart CL, Haney M, Collins ED, Rubin E, Foltin RW. Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses. Drug and Alcohol Dependence 2007;86(2-3):274-7.
50. Hatsukami D, Keenan R, Halikas J, Pentel PR, Brauer LH. Effects of carbamazepine on acute responses to smoked cocaine-base in human cocaine users. Psychopharmacology 1991;104:120-4.
51. Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence. CNS Drugs 2005;19(10):873-96.
52. Kampman KM, Leiderman D, Holmes T, LoCastro J, Bloch DA, Reid MS, et al. Cocaine rapid efficacy screening trials (CREST): lessons learned. Addiction 2005;100(Suppl 1):102-10.
53. Calabrese JR, Kemp DE, Ganocy SJ, et al. A 6-month, pilot, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for dual diagnosis rapid-cycling bipolar disorder. International Journal of Psychiatry in Clinical Practice. 2007; Vol. 11(Suppl 1):15-6.
54. Kemp DE, Gao K, Ganocy SJ, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. Journal of Clinical Psychiatry 2 2009;70(1):113-21.
55. Kuhn KL, Halikas JA, Kemp KD. Carbamazepine treatment of cocaine dependence in methadone maintenance patient with dual opiate-cocaine addiction. NIDA Research Monograph 1989;95:316-7.
56. Leiderman DB, Shoptaw S, Montgomery A, Bloch DA, Elkashef A, LoCastro JL, et al. Cocaine rapid efficacy screening trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. Addiction 2005;100(Suppl 1):1-11.
57. Llopis Llacer JJ, Aguilella AC. Efficacy of oxcarbazepine treatment in patients diagnosed with cocaine abuse/dependence. Adicciones 2008;20(3):263-70.
58. Mancino MJ, Feldman Z, Chopra M, Cargile CS, Oliveto A. Randomized placebo controlled trial of sertraline and sertraline plus gabapentin in depressed, recently abstinent cocaine-dependent patients. Proceedings of the 71th Annual Scientific Meeting of the College on Problems of Drug Dependence. Nevada USA: Reno/Sparks, 2009; Vol. 94.
59. Mancino MJ, McGaugh J, Chopra MP, et al. Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. Journal of Clinical Psychopharmacology 2014;34(2):234-9.
60. Mariani JJ, Pavlicova M, Bisaga A, Nunes EV, Brooks DJ, Levin FR. Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial. Biological Psychiatry 2012;72(11):950-6.
61. Reid MS, Casadonte P, Baker S, Sanfilippo M, Braunstein D, Hitzemann R, et al. A placebo-controlled screening trial of olanzapine, valproate and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100(Suppl 1):43-57.
62. Reid MS, Thakkar V. Valproate treatment and cocaine cue reactivity in cocaine dependent individuals. Drug and Alcohol Dependence 2009;102(1-3):144-50.
63. Reis AD, Castro LA, Faria R, Laranjeira R. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr 2008;30(2):132-5.
64. Salloum IM, Douaihy A, Cornelius JR, Kirisci L, Kelly TM, Hayes J. Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study. Addictive Behaviors 2007;32(2):410-5.
65. Sofuoglu M, Pentel PR, Bliss RL, Goldman AI, Hatsukami DK. Effects of phenytoin on cocaine self-administration in humans. Drug and Alcohol Dependence 1999;53(3):273-5.
66. Sofuoglu M, Poling J, Mitchell E, Kosten TR. Tiagabine affects the subjective response to cocaine in humans. Pharmacology, Biochemistry and Behavior 2005;82(3):569-73.
67. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Current Opinion in Psychiatry 2005;18:235-70.
68. Winther LC, Saleem R, McCance-Katz EF, Rosen MI, Hameedi FA, Pearsall HR, et al. Effects of lamotrigine on behavioral and cardiovascular responses to cocaine in human subjects. American Journal on Drug and Alcohol Abuse 2000;26(1):47-59.
69. Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J. Anticonvulsant drugs in the treatment of substance withdrawal. Drugs of Today 2004;40(7):603-19.
70. Gonzalez G, Romero-Gonzalez M, Desai R, et al. Myoclonus cases associated with tiagabine treatment for cocaine and opioid dependent patients. American Journal on Addictions 2009;18(4):324.
71. Llorens N, Perello MJ, Senchez A, et al. Exposuure techniques versus topiramate treatment on cocaine addiction. Proceedings of the 69th Annual Scientific Meeting of the College on Problems of Drug Dependence. Quebec City, Canada, 2007.
72. Sherwood Brown E, Sunderajan P, Hu LT, Sowell S, Carmody T. Lamotrigine in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology 2011;36:S425-6.
73. Effectiveness of topiramate in treating cocaine-dependent individuals. Ongoing study October 2005.
74. Tiagabine for the treatment of cocaine dependence. Ongoing study October 2002.
75. Novel pharmacotherapy for dual dependence. Ongoing study March 2007.
76. Effectiveness of tiagabine for cocaine dependence in methadone maintenance individuals. Ongoing study December 2004.
77. Efficacy of levetiracetam in cocaine-abusing methadone maintained patients (Keppra-DB). Ongoing study July 2007.
78. Vigabatrin for the treatment of cocaine dependency. Ongoing study January 2011.
79. A phase II, double-blind, placebo-controlled, pilot trial of vigabatrin for the treatment of cocaine and alcohol dependence. Ongoing study April 2011.
80. Multi-centre trial of combined pharmacotherapy to treat cocaine dependence (TACT2). Ongoing study Starting date of trial not provided. Contact author for more information.
81. New pharmacotherapeutic treatment options for crack cocaine-dependent people in the Netherlands. - CATCH-study. Ongoing study April 2010.
82. The use of topiramate in the crack addiction. Ongoing study February 2013.
83. Alvarez Y, Farré M, Fonseca F, Torrens M. Anticonvulsant drugs in cocaine dependence: a systematic review and meta-analysis. Journal of Substance Abuse Treatment 2010;38(1):66-73.
84. Amato L, Minozzi S, Pani PP, Davoli M. Antipsychotic medication for cocaine dependence. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006306.pub2]
85. Amato L, Minozzi S, Pani PP, Solimini R, Vecchi S, Zuccaro P, et al. Dopamine agonists for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003352.pub3]
86. Anton RF, Moak DH, Latham PK. The obsessive compulsive drinking scale:a new method of assessing outcome in alcoholism treatment studies. Archives of General Psychiatry 1996;53:225-31.
87. Beck AT, Word CH, Mendelson M, Mock J, Rebaugh J. An inventory for measuring depression. Archives of General Psichiatry 1961;4:461-71.
88. Campbell UC, Lac ST, Carroll ME. Effects of baclofen on maintenance and reinstatement of intravenous cocaine self-administration in rats. Psychopharmacology 1999;143(2):209-14.
89. Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD007380.pub3]
90. Cohen J, Dervaux A, Laqueille X. Topiramate in substance-related and addictive disorders. Presse Medicale 2014;43(9):892-901.
91. Crosby RD, Halikas JA, Carlson G. Pharmacotherapeutic interventions for cocaine abuse: present practices and future directions. Journal of Addictive Diseases 1991;10(4):13-30.
92. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Current Topics in Medicinal Chemistry 2005;5(1):3-14.
93. Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
94. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America 1988;85(14):5274-8.
95. Drevets WC, Price JC, Kupfer DJ, Kinahan PE, Lopresti B, Holt D, et al. PET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum. Neuropsychopharmacology 1999;21(6):694-709.
96. Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biological Psychiatry 2001;49(2):81-96.
97. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington DC: American Psychiatric Association, 1994.
98. EMCDDA The state of the drugs problem in the European Union and Norway. The State of the Drug Problem in the European Union and Norway. Luxemburg: European Monitoring Centre for Drug and Drug Abuse, 2006.
99. EMCDDA The State of the Drug Problem in Europe. Annual Report. Luxemburg: European Monitoring Centre for Drug and Drug Abuse, 2012.
100. EMCDDA European Drug Report: Trends and Developments. European Drug Report: Trends and Developments. Luxemburg: European Monitoring Centre for Drugs and Drug Addiction, 2014.
101. The GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490-4.
102. Guy W. Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington DC: US Department of Health Education and Welfare, 1976.
103. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924-6.
104. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64:383-94.
105. Halikas JA, Kuhn KL, Crosby R, Carlson G, Crea F. The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Comprehensive Psychiatry 1991;32:22-7.
106. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50-5.
107. Hamilton M. Development of a rating scale for primary depressive illness. British Journal of Social and Clinical Psychology 1967;6(4):278-96.
108. Harvey JA. Cocaine effects on the developing brain: current status. Neuroscience & Biobehavioral Reviews 2004;27(8):751-64.
109. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org, 2011.
110. Karila L, Reynaud M, Aubin HJ, Rolland B, Guardia D, Cottencin O, Benyamina A. Pharmacological treatments for cocaine dependence: is there something new?. Current Pharmaceutical Design 2011;17(14):1359-68.
111. Knapp WP, Soares BGO, Farrel M, Lima MS. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006754.pub3.]
112. Koob GF, Nestler EJ. The neurobiology of drug addiction. Journal of Neuropsychiatry and Clinical Neurosciences 1997;9(3):482-97.
113. Kranzler HR, Bauer LO, Hersh D, Klinghoffer V. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug and Alcohol Dependence 1995;38(3):203-11.
114. Kushner SA, Dewey SL, Kornetsky C. The irreversible gamma-aminobutyric acid (GABA) transaminase inhibitor gamma-vinyl-GABA blocks cocaine self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 1999;290(2):792-802.
115. Landmark CJ. Targets for antiepileptic drugs in the synapse. Medical Science Monitor 2007;13(1):RA1-7.
116. Lima Reisser A, Lima MS, Soares BGO, Farrell M. Carbamazepine for cocaine dependence. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD002023.pub2]
117. McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The fifth edition of the Addiction Severity Index. Journal Substance Abuse Treatment 1992;9(3):199-213.
118. Minozzi S, Amato L, Davoli M, Farrell MF, Lima Reisser AARL, Pani PP, et al. Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006754.pub3]
119. Mulvaney FD, Alterman AI, Boardman CR, Kampman K. Cocaine abstinence symptomatology and treatment attrition. Journal of Substance Abuse Treatment 1999;16:129-35.
120. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2011.
121. Pani PP, Trogu E, Vacca R, Amato L, Vecchi S, Davoli M. Disulfiram for the treatment of cocaine dependence. Cochrane Database of Systematic Reviews 2010, Issue 1. [: 10.1002/14651858.CD007024.pub2]
122. Pani PP, Trogu E, Vecchi S, Amato L. Antidepressants for cocaine dependence and problematic cocaine use. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD002950.pub3]
123. Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. Journal of Clinical Psychiatry 2010;71(5):634-48.
124. Schünemann HJ, Jaeschke R, Cook D, Bria W, El-Solh A, Ernst A, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. American Journal of Respiratory and Critical Care Medicine 2006;174:605-14.
125. Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M. In search of a universal drug craving scale. Annual Meeting of the American Psychiatric Association. 1995.
126. Spielberg DC. State-Trate Anxiety Inventory. Palo Alto CA: Consulting Psychologist Press, 1983.
127. UNODC, World Drug Report 2013 (United Nations publication, Sales No. E.13.XI.6).
128. Volkow ND, Fowler JS, Wang GJ. The addicted human brain: insights for imaging studies. Journal of Clinical Investigation 2003;111(10):1444-51.